What Are the Long-Term Effects of Semaglutide? What the Research Shows

If you have been taking semaglutide for several months, or you are considering starting, one question comes up again and again: what happens to your body over the long term? The early results are compelling, but what does ongoing use actually look like in the research? Are there risks that emerge over time? What about your heart, your bones, your muscle mass?

These are reasonable questions. And the research, while still maturing, gives us a meaningful starting point.

This article walks through what peer-reviewed studies say about the long-term effects of semaglutide, including benefits that accumulate over time, risks worth knowing about, and what happens if you stop.

*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only. It does not constitute medical advice. Results vary by individual. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

Long-Term Weight Loss: What the Data Shows

The question most people care about first is whether semaglutide keeps working over months and years, or whether results plateau and reverse.

The STEP 5 trial provides some of the clearest long-term weight loss data available. Over 104 weeks (two full years), participants receiving semaglutide 2.4 mg weekly maintained a mean body weight reduction of 15.2%, compared to 2.6% in the placebo group. Weight loss did not simply reverse after the initial months. For most participants, results held or continued improving through the two-year observation period.

This is meaningful. Earlier obesity medications often produced rapid early results followed by a rebound effect. The two-year trajectory for semaglutide looks more durable.

That said, the STEP 5 data also shows that results are not indefinite on their own. Weight loss typically reaches its maximum effect somewhere between months 12 and 16, after which it tends to stabilize rather than continue declining. Maintaining that lower weight requires ongoing treatment (discussed more in the section on stopping the medication).

What "Long-Term" Means in the Research

Most of the available data extends to two to four years. The SELECT trial, published in 2023, followed over 17,600 adults for a median of 3.3 years, making it the largest and longest semaglutide study to date. Long-term data beyond five years is still limited, which is worth being honest about. The research community is actively collecting this data, but medicine has not yet had decades of semaglutide use to study.

---

Cardiovascular Benefits Over Time

One of the most significant findings in long-term semaglutide research has nothing to do with the scale. It concerns your heart.

The SELECT trial ([PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131)) enrolled 17,604 adults with established cardiovascular disease who were overweight or obese but did not have diabetes. The study's primary endpoint was major adverse cardiovascular events (MACE): heart attack, stroke, or cardiovascular death. Over 3.3 years, semaglutide reduced MACE by 20% compared to placebo.

This result stood independent of how much weight participants lost, suggesting the cardiovascular benefit is not only about weight reduction. Researchers believe semaglutide's effects on inflammation, blood pressure, and lipid levels contribute independently to cardiac protection.

The earlier SUSTAIN-6 trial ([PMID: 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186)) showed similar cardiovascular benefits in people with type 2 diabetes over two years, establishing a consistent pattern across different populations.

For anyone taking semaglutide long term, particularly those with cardiovascular risk factors, this data is meaningfully reassuring.

---

*Regular provider check-ins are an important part of long-term treatment. Your provider monitors your progress, adjusts dosing, and evaluates any changes to your health profile over time.*

---

Long-Term Safety: What to Know

Thyroid Concerns

You may have seen warnings about thyroid cancer on semaglutide prescribing information. The background: in rodent studies, semaglutide caused thyroid C-cell tumors at high doses. This finding is required to appear on the label.

However, human clinical trials and post-market surveillance have not found an increased risk of thyroid C-cell cancer in people. Humans and rodents have different GLP-1 receptor distributions in thyroid tissue, which may explain the species difference. Current evidence does not establish a causal link between semaglutide and thyroid cancer in humans.

People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not use semaglutide. If you have concerns about thyroid health, discuss them with your provider.

Pancreatitis Risk

Some GLP-1 medications were investigated for a possible pancreatitis link in earlier years. For semaglutide specifically, large long-term trials including SELECT and SUSTAIN-6 have not found a statistically significant increase in pancreatitis rates compared to placebo. The SELECT trial followed over 17,000 patients for more than three years with no elevated pancreatitis signal.

People with a history of pancreatitis or certain pancreatic conditions are typically not candidates for semaglutide. For others, the available long-term data is reassuring.

Gallbladder Effects

Rapid weight loss of any kind increases the risk of gallstones. Because semaglutide facilitates significant weight reduction, a modestly elevated gallstone risk is documented in the research. STEP trial data showed a higher rate of gallbladder-related events in the semaglutide group compared to placebo.

This does not mean gallstones are inevitable. It means the risk exists and is worth monitoring, particularly in people with prior gallbladder issues. Staying adequately hydrated and losing weight at a gradual pace (which semaglutide typically facilitates) helps reduce this risk.

Gastrointestinal Effects Over Time

Nausea, constipation, and other GI effects are common early in semaglutide treatment, particularly during dose escalation. For most people, these symptoms improve substantially after the first three to six months as the body adjusts. Long-term data from the STEP trials confirms that GI adverse events decline in frequency over time. Most people who reach their maintenance dose report that GI symptoms are either minimal or manageable.

---

Bone Density and Muscle Mass

A legitimate long-term concern for people losing significant weight is what happens to bone density and lean muscle mass. Rapid weight loss, particularly in older adults, can accelerate muscle and bone loss independent of the medication itself.

Research has documented modest reductions in bone mineral density in people treated with semaglutide. These reductions appear to be related primarily to the weight loss itself rather than a direct effect of the medication.

The practical implication: adequate protein intake and resistance training become more important, not less, during long-term semaglutide treatment. Studies suggest that people who maintain higher protein intake and engage in regular resistance exercise preserve substantially more lean muscle mass during GLP-1 therapy. Your provider may recommend strength training alongside your medication protocol for this reason.

---

*Resistance training and adequate protein intake help preserve lean muscle mass during long-term semaglutide therapy. These lifestyle factors matter increasingly the longer you are on treatment.*

---

What Happens When You Stop Semaglutide

This is one of the most discussed topics in long-term semaglutide research, and the data is both honest and important to understand.

The STEP 1 extension study followed participants for one year after they stopped semaglutide. By the end of that year, participants had regained approximately two-thirds of the weight they had lost during the trial. Cardiometabolic improvements made during treatment (reductions in blood pressure, improved lipid profiles, lower blood sugar) also reversed substantially after stopping.

This does not mean semaglutide failed. It means the medication works while you are taking it, much like a medication for blood pressure or cholesterol. The underlying biology that drives weight gain does not disappear after you stop. For many people, semaglutide is a long-term or indefinite therapy rather than a short-term treatment.

If you are considering stopping semaglutide, discuss the timing and approach with your provider. There are protocols for tapering rather than stopping abruptly, and your provider can help you develop a maintenance plan that gives you the best chance of sustaining your results.

For more on this topic, see [What Happens When You Stop Semaglutide](/articles/what-happens-when-you-stop-semaglutide).

---

Putting It Together

The long-term picture on semaglutide is more complete than it was even a few years ago. The main takeaways from the research:

• Weight loss holds over two years for most people who continue treatment, with results stabilizing rather than reversing during ongoing use
• Cardiovascular protection accumulates over time, with a 20% reduction in major cardiac events over 3.3 years in the SELECT trial
• The most serious safety concerns (thyroid cancer, pancreatitis) have not been confirmed in human long-term trials; the documented risks (gallstones, modest bone density changes) are manageable with monitoring
• GI side effects improve substantially after the first few months for most people
• Stopping treatment typically leads to weight regain, which means long-term use may be appropriate for many people as part of an ongoing metabolic health strategy

What the research does not yet offer is data beyond four to five years. That does not mean long-term use is unsafe; it means the evidence base is still growing.

If you have specific concerns about long-term effects given your personal health history, the most useful thing you can do is raise them directly with your provider. They can help you weigh the evidence against your individual risk profile.

---

Talk to Your Provider

If you are currently on semaglutide and thinking about the long term, or if you are evaluating whether to start, a licensed provider can help you understand how the research applies to your specific situation.

At Prescriva, our medical team works with you to develop a treatment plan that reflects your goals and your health history. If you have not yet had a consultation, [start your assessment](/get-started) to connect with a provider.

---

Sources

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). *N Engl J Med*. 2023;389(24):2221-2232. [PMID: 37952131](https://pubmed.ncbi.nlm.nih.gov/37952131)

1. Marso SP, Daniels GH, Brown-Frandsen K, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). *N Engl J Med*. 2016;375(19):1834-1844. [PMID: 27633186](https://pubmed.ncbi.nlm.nih.gov/27633186)

1. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nat Med*. 2022;28(10):2083-2091. [PMID: 36216945](https://pubmed.ncbi.nlm.nih.gov/36216945)

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. *Diabetes Obes Metab*. 2022;24(8):1553-1564. [PMID: 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470)

*Results vary. Compounded semaglutide is not FDA-approved. Prescriva is a management services organization; clinical care is provided by licensed independent practitioners. This content has been prepared for informational purposes and does not constitute medical advice. Always consult a licensed healthcare provider before starting, adjusting, or stopping any medication.*